CAH

The provided SEC-sourced fundamentals show multi-quarter top-line growth and rising gross profit alongside improving operating income and net income, which together present a company operating with expanding scale and profitability on a quarterly basis (evidence: company 10-K/10-Q figures — strong). Weighted-average diluted shares outstanding declined each quarter, and recurring repurchase activity is reported, which aligns with the reduction in share count and supports per-share metrics (evidence: repurchase and share counts in filings — moderate-to-strong). Liquidity appears healthy on a balance-sheet basis: cash exceeds long-term debt by roughly $2.35B and enterprise-value/EBITDA is 14.23 while trailing EBITDA is positive $3.495B (evidence: valuation and balance sheet figures — strong). Institutional ownership and multiple recent analyst buy/initiations in the street consensus, plus media coverage emphasizing the company’s strategic shift to specialty and at‑home healthcare, indicate meaningful market interest that complements the operational signals (evidence: 13F holdings and news items — moderate). These points mitigate concerns about negative trailing free cash flow and negative stockholders’ equity by showing operational profitability, improving cash buffers, and active capital-return behavior in the evidence set (negative FCF and negative equity are recorded but contextualized by cash > debt and positive EBITDA — mixed strength).